Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 2

2(40.0%)

Phase 1

1(20.0%)

5Total

Phase 3(2)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02488629Phase 2Terminated

Study of SCB01A in Patient With Head and Neck Cancer

Role: lead

NCT03020823Phase 2Terminated

To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer

Role: lead

NCT03126435Phase 3Completed

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

Role: lead

NCT03002103Phase 3Suspended

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Role: lead

NCT01151930Unknown

Long-Term Compassionate Use Study for Continued Administration of SCB01A-01

Role: lead

NCT01159522Phase 1Completed

A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy

Role: lead

All 6 trials loaded